Disc Medicine, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John D. Quisel
- Full Time Employees
- 94
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 321 Arsenal Street Watertown MA United States of America 02472
- IPO Date
- Aug 12, 2020
- CIK
- 0001816736
- Website
- discmedicine.com
- Similar Companies
- Business
- Disc Medicine, Inc. (Nasdaq: IRON) develops novel therapies targeting red blood cell biology pathways, including heme biosynthesis and iron homeostasis, for patients with serious hematologic diseases such as anemias and polycythemia. The company offers a clinical-stage pipeline featuring bitopertin, a glycine transporter 1 inhibitor for erythropoietic porphyrias including erythropoietic protoporphyria and X-linked protoporphyria, as well as Diamond-Blackfan anemia; DISC-0974, a hepcidin inhibitor for anemia of myelofibrosis and anemia of chronic kidney disease; DISC-3405, a monoclonal antibody against transmembrane serine protease 6 licensed from Mabwell Therapeutics for polycythemia vera and other myeloproliferative neoplasms; and preclinical DISC-0998 for anemia associated with inflammatory diseases. Disc Medicine conducts operations in the United States and pursues global development opportunities through clinical trials and regulatory submissions. Founded in 2017, the company maintains headquarters at 321 Arsenal Street, Suite 101, Watertown, Massachusetts. Recent developments include submission of a New Drug Application for accelerated approval of bitopertin in erythropoietic protoporphyria on September 29, 2025, following a positive pre-NDA meeting with the FDA and receipt of a Commissioner's National Priority Voucher in October 2025; an upsized $250 million public offering in late 2025 raising approximately $211 million in net proceeds to extend cash runway into 2029; completion of a $200 million non-dilutive debt financing facility with Hercules Capital in 2024 providing up to $110 million in available funding; presentation of initial Phase 2 data for DISC-0974 in myelofibrosis anemia and DISC-3405 in polycythemia vera at the ASH Annual Meeting in December 2025; and advancement of multiple ongoing trials including Phase 1b DISC-3405 in sickle cell disease initiated in October 2025.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
FIVE IRON GOLF FORT WORTH WELCOMES CHARLES SCHWAB CHALLENGE FANS WITH TOURNAMENT-WEEK EXPERIENCES, WATCH PARTIES AND FREE GOLF FOR ANYONE NAMED CHARLES
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON